Summary
Lemonade Inc. shares declined in morning trading after a prominent Wall Street firm reduced its recommendation. Morgan Stanley downgraded the stock from Overweight to Equalweight while holding its $75 price target, and smaller but still significant analyst pressure came from Keefe, Bruyette & Woods, which kept an Underperform rating with a $48 target. The move followed a rapid advance in Lemonade shares of about 50% over the previous month and coincided with a broadly softer market.
What happened
Shares of Lemonade slipped 9.1% during morning trading after Morgan Stanley stepped back from a previously bullish stance. The firm retained a $75 price objective but said the stock’s recent strong run reduced the near-term attractiveness of the risk-reward profile, and indicated it would wait for a material new catalyst before revisiting its view.
Morgan Stanley nevertheless reiterated its underlying conviction in Lemonade’s model, pointing to the company’s tech-enabled growth trajectory and what it described as improving underwriting momentum. The firm projects Lemonade is positioned to exit 2027 with net income profitability.
Analyst divergence and market context
Adding to downward pressure, Keefe, Bruyette & Woods kept an Underperform rating on the stock, with a price target moved modestly higher to $48 from $44. That contrast between Morgan Stanley’s maintained target and KBW’s bearish view contributed to a notable divergence among sell-side analysts compared with the stock’s recent trading levels.
The broader market offered little support. The S&P 500 was down 0.6%, the Dow Jones Industrial Average fell 1.0%, and the Nasdaq retreated 0.5% during the session, amplifying stock-specific volatility for a company known for elevated swings in its share price.
Operational notes and intraday movement
Despite the sell-off, company-level developments cited in coverage remain intact: Lemonade has been expanding the geographic footprint of its renters insurance product and has put in place a renewed reinsurance program. Still, the combined headwind of downgrades and a soft macro backdrop pushed the stock to an intraday low of $70.31.
Takeaway
The sell-side reassessment centered on valuation after a rapid monthly gain, not on a reversal of the firm-level view that Lemonade can scale profitably by the end of 2027. Where the next significant catalyst emerges will likely guide the next change in analyst positioning.